- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07623031
Dual-Language B-MORE for Hypertension
maanantai 31. elokuuta 2026 päivittänyt: Adam Hanley, Florida State University
B-MORE for Hypertension
This pilot study is a single-arm clinical feasibility trial evaluating the feasibility, acceptability, and preliminary efficacy of a brief adaptation of Mindfulness-Oriented Recovery Enhancement (B-MORE) for reducing stress and high blood pressure in hypertensive English- and Spanish-speaking patients (n=20).
The intervention, a 2-hour online training in stress management and hypertension, will be delivered virtually in a small-group format over two 60-minute sessions.
Tutkimuksen yleiskatsaus
Tila
Aktiivinen, ei rekrytointi
Opintotyyppi
Interventio
Ilmoittautuminen (Arvioitu)
20
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
Florida
-
Orlando, Florida, Yhdysvallat, 32805
- Shepherd's Hope Downtown Clinic
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Ei
Kuvaus
Inclusion Criteria:
- Age ≥18
- Having self-reported hypertension (BP ≥ 140/90)
- Understanding English or Spanish instructions fluently
Exclusion Criteria:
- Known or planned pregnancy in the next 3 months assessed via self-report
- Cognitive impairment preventing completion of study procedures.
- Have previous, formal mindfulness training (e.g., MBSR)
- Other unstable illness judged by medical staff to interfere with study involvement.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Muut
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: B-MORE (Brief Mindfulness-Oriented Recovery Enhancement)
Participants will receive a remotely-delivered mindfulness-based intervention (B-MORE) consisting of two 60-minute small group sessions conducted over two weeks.
The intervention includes mindfulness training, cognitive reappraisal, and positive emotion regulation techniques.
|
B-MORE is a validated, two-hour adaptation of the evidence-based MORE program.
It retains each of the three, core therapeutic elements of the traditional MORE program (mindfulness, reappraisal, savoring) and is organized for delivery in two, 1-hour sessions.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Feasibility of the B-MORE intervention for Stress
Aikaikkuna: The expected time frame is from baseline to study completion, an average of 10 weeks.
|
The feasibility of the B-MORE intervention for managing stress in hypertensive patients will be assessed using recruitment metrics.
Specifically, feasibility will be based on the recruitment rate, defined as the number of participants recruited and enrolled per week.
Feasibility will also be based on session attendance metrics, defined as the percentage of participants who complete the first B-MORE session and the second B-MORE session.
Finally, feasibility will be based on retention rates, defined as the percentage of participants completing all treatment sessions and study surveys.
|
The expected time frame is from baseline to study completion, an average of 10 weeks.
|
|
Feasibility of the B-MORE intervention for Blood Pressure
Aikaikkuna: The expected time frame is from baseline to study completion, an average of 10 weeks.
|
The feasibility of the B-MORE intervention for managing blood pressure in hypertensive patients will be assessed using recruitment metrics.
Specifically, feasibility will be based on the recruitment rate, defined as the number of participants recruited and enrolled per week.
Feasibility will also be based on session attendance metrics, defined as the percentage of participants who complete the first B-MORE session and the second B-MORE session.
Finally, feasibility will be based on retention rates, defined as the percentage of participants completing all treatment sessions and study surveys.
|
The expected time frame is from baseline to study completion, an average of 10 weeks.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Treatment Acceptability for the B-MORE intervention for Stress
Aikaikkuna: Measured through participant self-report at the completion of the B-MORE program (immediately post-intervention and at 2-week and 6-week follow-up assessments).
|
The acceptability of the B-MORE intervention for managing stress in hypertensive patients will be based on participant self-report at the completion of the B-MORE program and at the 2- and 6-week follow-up assessments.
More specifically, a 4-item Treatment Acceptability and Preferences questionnaire rated on a 5-point Likert Scale ("Not at all" to "Very Much") will be used for treatment acceptability.
The scores from these 4 items will be summed and averaged to calculate an average score between 1 and 5, with a higher average scores indicating greater treatment acceptability.
|
Measured through participant self-report at the completion of the B-MORE program (immediately post-intervention and at 2-week and 6-week follow-up assessments).
|
|
Treatment Acceptability for the B-MORE intervention for Blood Pressure
Aikaikkuna: Measured through participant self-report at the completion of the B-MORE program (immediately post-intervention and at 2-week and 6-week follow-up assessments).
|
The acceptability of the B-MORE intervention for managing blood pressure in hypertensive patients will be based on participant self-report at the completion of the B-MORE program and at the 2- and 6-week follow-up assessments.
More specifically, a 4-item Treatment Acceptability and Preferences questionnaire rated on a 5-point Likert Scale ("Not at all" to "Very Much") will be used for treatment acceptability.
The scores from these 4 items will be summed and averaged to calculate an average score between 1 and 5, with a higher average scores indicating greater treatment acceptability.
|
Measured through participant self-report at the completion of the B-MORE program (immediately post-intervention and at 2-week and 6-week follow-up assessments).
|
|
Treatment Expectancy for the B-MORE Intervention
Aikaikkuna: Measured through participant self-report at the completion of the B-MORE program (immediately post-intervention).
|
Treatment expectancy for the B-MORE intervention will be based on participant self-report at the completion of the B-MORE program and at the 2- and 6-week follow-up assessments.
More specifically, a 4-item Credibility/Expectancy Questionnaire rated on a sliding scale from "Not at all" to "Very Much" will be used for treatment expectancy and credibility, with higher ratings indicating greater treatment expectancy.
|
Measured through participant self-report at the completion of the B-MORE program (immediately post-intervention).
|
|
Treatment Satisfaction with the B-MORE Intervention
Aikaikkuna: Measured through participant self-report at the completion of the B-MORE program (immediately post-intervention and at the 2- and 6-week follow up points).
|
Treatment satisfaction with the B-MORE intervention will be based on participant self-report at the completion of the B-MORE program and at the 2- and 6-week follow-up assessments.
More specifically, a 3-item questionnaire with qualitative questions on the patient experience (e.g., "Was the program accessible?
If not, what barriers did you encounter?" and "What were the best or most useful elements of the program?") will be used for treatment satisfaction.
|
Measured through participant self-report at the completion of the B-MORE program (immediately post-intervention and at the 2- and 6-week follow up points).
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in Psychological Stress (Physiological)
Aikaikkuna: Expected time frame is baseline to study completion, approximately 10 weeks. Heart rate and stress-related measures recorded daily.
|
Physiological data, including heart rate variability (HRV) collected via Garmin watches.
|
Expected time frame is baseline to study completion, approximately 10 weeks. Heart rate and stress-related measures recorded daily.
|
|
Adverse Effects of the B-MORE Intervention
Aikaikkuna: Measured through participant self-report at the completion of the B-MORE program (immediately post-intervention).
|
Adverse effects of the B-MORE intervention will be based on participant self-report at the completion of the B-MORE program and at the 2- and 6-week follow-up assessments.
More specifically, a 2-item measure on unwanted or unpleasant experiences during or after the training sessions (e.g., "Did you experience any unwanted or unpleasant experiences during or after the training?")
will be used for evaluating adverse effects.
|
Measured through participant self-report at the completion of the B-MORE program (immediately post-intervention).
|
|
Change in Diastolic Blood Pressure
Aikaikkuna: Measured at baseline, before and after each intervention session, immediately post-intervention, and at 2-week and 6-week follow-up assessments. Daily BP measurements will also be taken.
|
Self-measured diastolic blood pressure using a provided blood pressure cuff.
|
Measured at baseline, before and after each intervention session, immediately post-intervention, and at 2-week and 6-week follow-up assessments. Daily BP measurements will also be taken.
|
|
Change in Systolic Blood Pressure
Aikaikkuna: Measured at baseline, before and after each intervention session, immediately post-intervention, and at 2-week and 6-week follow-up assessments. Daily BP measurements will also be taken.
|
Self-measured systolic blood pressure using a provided blood pressure cuff.
|
Measured at baseline, before and after each intervention session, immediately post-intervention, and at 2-week and 6-week follow-up assessments. Daily BP measurements will also be taken.
|
|
Change in State Anxiety
Aikaikkuna: Expected time frame is 2 weeks. Measured immediately before and after each of the 2 intervention sessions.
|
Changes in state anxiety will be based on a single-item self-report question on acute anxiety symptoms ("How nervous, anxious, or on edge do you feel right now?").
It will be rated on a 0-10 numeric rating scale, with 0 being no anxiety at all and 10 being anxiety as bad as you can imagine.
It will be measured immediately before and immediately after the B-MORE sessions.
|
Expected time frame is 2 weeks. Measured immediately before and after each of the 2 intervention sessions.
|
|
Change in Trait Anxiety
Aikaikkuna: Expected time frame is baseline to study completion, approximately 10 weeks. Measured at baseline, immediately post-intervention, and at 2-week and 6-week follow-up assessments.
|
Changes in trait anxiety will be based on the Generalized Anxiety Disorder-2, a 2-item questionnaire rated on 4-point Likert scale from "Not at all" to "Nearly every day."
The scores from these 2 items will be summed to calculate a total score between 0 and 6, with higher scores (3 or higher) indicating greater anxiety symptoms.
It will be completed at baseline, immediately post-intervention, and at the 2- and 6-week follow-up assessments.
|
Expected time frame is baseline to study completion, approximately 10 weeks. Measured at baseline, immediately post-intervention, and at 2-week and 6-week follow-up assessments.
|
|
Change in Trait Depression
Aikaikkuna: Expected time frame is baseline to study completion, approximately 10 weeks. Measured at baseline, immediately post-intervention, and at 2-week and 6-week follow-up assessments.
|
Changes in trait depression will be based on the Depression with the Patient Health Questionnaire-2, a 2-item questionnaire rated on 4-point Likert scale from "Not at all" to "Nearly every day."
The scores from these 2 items will be summed to calculate a total score between 0 and 6, with higher scores (3 or higher) indicating greater depression symptoms.
It will be completed at baseline, immediately post-intervention, and at the 2- and 6-week follow-up assessments.
|
Expected time frame is baseline to study completion, approximately 10 weeks. Measured at baseline, immediately post-intervention, and at 2-week and 6-week follow-up assessments.
|
|
Change in Quality of Life
Aikaikkuna: Expected time frame is baseline to study completion, approximately 10 weeks. Measured at baseline, immediately post-intervention, and at 2-week and 6-week follow-up assessments.
|
Changes in quality of life will be based on the WHO-5 Well-Being Index, a 5-item questionnaire rated on a 0-5 numeric rating scale, with 0 being "At no time" and 5 being "All of the time."
The scores from all 5 items will be summed to calculate a raw score between 0 and 25 and then multiplied to calculate a percentage score between 0 and 100, with higher percentages indicating greater mental well-being.
It will be completed at baseline, immediately post-intervention, and at the 2- and 6-week follow-up assessments.
|
Expected time frame is baseline to study completion, approximately 10 weeks. Measured at baseline, immediately post-intervention, and at 2-week and 6-week follow-up assessments.
|
|
Change in Hypertension Symptomology
Aikaikkuna: Expected time frame is baseline to study completion, approximately 10 weeks. Measured at baseline, immediately post-intervention, and at 2-week and 6-week follow-up assessments.
|
Changes in hypertension symptomology will be based on the Mini Cuestionario de Calidad de Vida en Hipertensión Arterial (MINICHAL), a 16-item questionnaire rated on a 4-point Likert scale from "No, not at all" (0) to "Yes, a lot" (3).
Scores from items 1-10 will be summed to calculate a total score for the State of Mind Domain.
This total score will range from 0 to 30, with higher scores indicating worse mental well-being due to hypertension.
Scores from items 11-16 will be summed to calculate a total score for the Somatic Manifestations Domain.
This total score will range from 0 to 18, with higher scores indicating more severe physical symptoms due to hypertension.
It will be completed at baseline, immediately post-intervention, and at the 2- and 6-week follow-up assessments.
|
Expected time frame is baseline to study completion, approximately 10 weeks. Measured at baseline, immediately post-intervention, and at 2-week and 6-week follow-up assessments.
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Perjantai 5. kesäkuuta 2026
Ensisijainen valmistuminen (Arvioitu)
Sunnuntai 1. marraskuuta 2026
Opintojen valmistuminen (Arvioitu)
Tiistai 1. joulukuuta 2026
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Tiistai 5. toukokuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Maanantai 1. kesäkuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Keskiviikko 3. kesäkuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Keskiviikko 2. syyskuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Maanantai 31. elokuuta 2026
Viimeksi vahvistettu
Maanantai 1. kesäkuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- STUDY00007273 Shepherd's Hope
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
JOO
IPD-suunnitelman kuvaus
Individual participant data will be shared with qualified individuals upon request.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .